Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant Erwinia asparaginase

Erwinia asparaginase
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Recombinant Erwinia asparaginase, covering 2026-02-06 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia [Phase 1]

See pricing